I-131-Apamistamab |
131IBC8; BC8-I-131; BC-8 |
Phase 3 Clinical |
Fred Hutchinson Cancer Research Center |
Leukemia, Myeloid, Acute; Sezary Syndrome; Neoplasms, Gonadal Tissue; Waldenstrom Macroglobulinemia; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Intraocular Lymphoma; Lymphoma, T-Cell; Pancytopenia; Lymphoma, T-Cell, Cutaneous; Anemia, Sideroblastic; Lymphoma, Large-Cell, Anaplastic; Leukemia, T-Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Hematopoietic stem cell transplantation (HSCT); Leukemia; Neoplastic Cells, Circulating; Leukemia, Hairy Cell; Anemia, Refractory, with Excess of Blasts; Hodgkin Disease; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Lymphomatoid Granulomatosis; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell |
Details
|